Our findings indicate that a 25 μg dose of the Xcl1-E6E7+mIL-9 vaccine is sufficient to completely eradicate subcutaneous TC-1 tumors, which achieved complete tumor clearance in about 60% of the mice (Figure 5C). Here, XCL1 is linked to neoplasm.